期刊
CANCER MEDICINE
卷 7, 期 11, 页码 5457-5469出版社
WILEY
DOI: 10.1002/cam4.1808
关键词
BCR-ABL; chronic myeloid leukemia; symptom burden; tyrosine kinase inhibitors
类别
资金
- MD Anderson Cancer Center [CA016672]
- Bristol-Myers Squibb
- Novartis Pharma
- Ariad Pharmaceuticals
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Background Treatment with tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) is effective but needs to continue for several years, possibly indefinitely. Although generally safe, TKI may have hitherto poorly recognized effects in the quality of life (QoL) of such patients. Methods Results The median age was 50 years. Longitudinal analysis showed relatively stable symptom severity scores over time. Fatigue was the most common symptom in all three cohorts, both prior to the start of therapy and during therapy, including after achievement of deep molecular remission. Work was the most affected component of daily living. Overall patients tolerated therapy well with improvement of their symptoms from baseline, with few dose reductions related to toxicity or symptomatology. Although 31% of the patients who completed MDASI-CML achieved complete molecular remission by 24 months of treatment, nearly 90% experienced persistent mild symptoms. Conclusion Side effects related to TKIs may impact the quality of life in patients with CML-CP. Further studies should investigate factors (comorbidities, concomitant medications, dose and schedule, etc) associated with these symptoms and interventions that may improve the patients' QoL, including treatment discontinuation when safely feasible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据